{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:55:19Z","timestamp":1771656919007,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,10,20]],"date-time":"2008-10-20T00:00:00Z","timestamp":1224460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The role of post\u2010chemotherapy booster vaccination in pediatric oncology children remains to be established. In this randomized controlled study, we studied the effect of immune responses to diphtheria\u2013tetanus\u2013pertussis (DTP) booster vaccination in children 6 months after completing chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Children 1\u201318 years old with chemotherapy completed for 6 months (baseline) were eligible. Subjects were randomized into vaccine and control group. In the former, three doses of DTP vaccine (Aventis Pasteur Inc., Lyon, France) were administered. IgG antibody titers against diphtheria, tetanus, pertussis, hepatitis B, measles, mumps, and rubella antibodies were measured serially in vaccine and control groups. Subsets of circulating lymphocytes (CD3<jats:sup>+<\/jats:sup>, CD4<jats:sup>+<\/jats:sup>, CD8<jats:sup>+<\/jats:sup>, CD19<jats:sup>+<\/jats:sup>, and CD16\/56<jats:sup>+<\/jats:sup>) were quantified by flow cytometry using fluorescence\u2010labeled monoclonal antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010six children (28 vaccinees; 28 controls) were enrolled. Protective antibody levels against diphtheria, tetanus, pertussis were found at baseline in 83.6%, 96.5%, 96.1% of them respectively. After three doses of DTP, all vaccinees demonstrated a sustain rise in antibody levels and the antibody titers were significantly higher than control group. 35.8% of subjects were susceptible to measles mumps and rubella infection and 69% showed anti\u2010HBs antibody titer less than protective level up to 18 months after stopping chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Post\u2010chemotherapy booster vaccinations produced a strong and sustained effect in humoral immunity against vaccine\u2010preventable infectious diseases. Pediatr Blood Cancer 2009;52:248\u2013253. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.21792","type":"journal-article","created":{"date-parts":[[2008,10,20]],"date-time":"2008-10-20T16:19:30Z","timestamp":1224519570000},"page":"248-253","source":"Crossref","is-referenced-by-count":9,"title":["Humoral immune response after post\u2010chemotherapy booster diphtheria\u2013tetanus\u2013pertussis vaccine in pediatric oncology patients"],"prefix":"10.1002","volume":"52","author":[{"given":"Frankie Wai Tsoi","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting Fan","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Kay Sheung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Kong","family":"Shing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Wai","family":"Chik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Man Pan","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Kong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,5]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"243","article-title":"Impact of vaccines universally recommended for children\u2014United States, 1990\u20131998","volume":"48","author":"Centers for Disease Control Prevention","year":"1999","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21346"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704870"},{"key":"e_1_2_6_5_2","first-page":"659","article-title":"The Infectious Disease Society of America and the American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"6","author":"CDC","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_6_6_2","unstructured":"Immunization of the immunocompromised child: Best practice statement. Royal College of Paediatric and Child Health (RCPCH) 2002."},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0891-5520(20)30327-5","article-title":"Approach to immunization in the immunocompromised host","volume":"4","author":"Hibberd PL","year":"1990","journal-title":"Infect Dis Clin North Am"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/pch\/6.6.379","article-title":"Practical vaccination guidelines for children with cancer","volume":"6","author":"Sung L","year":"2001","journal-title":"Pediatr Child Health"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920315)69:6<1481::AID-CNCR2820690628>3.0.CO;2-L"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019409141671"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20384"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21327"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21277"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/511641"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/511636"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00441492"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20255"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.6.e91"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.7.2221.2221"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/514661"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540310016600"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21792","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T21:14:46Z","timestamp":1699910086000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1002\/pbc.21792"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21792","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,5]]}}}